Skip to main content
2025 AATOD Conference Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Evaluation Video ViewAttendees 2

Pre-Conference

Community Partners & Continuum of Care

PC12 - From Silos to Synergy: Cross-Sector Partnerships to Address Hepatitis in Opioid Treatment Programs and other Key Settings

Sunday, October 5, 2025
9:00am - 12:30pm EST
Location: Salon J
Earn 3.5 CE Hour(s)
Presentation Summary: Viral hepatitis is one of the key health issues affecting people who have ever injected drugs in the United States. In recent years there have been renewed efforts to eliminate hepatitis at local, state and national levels that center people with lived experience and support multidisciplinary collaboration.

As the opioid treatment landscape continues to evolve, so too must our approaches to addressing co-occurring public health challenges such as viral hepatitis. This session will explore opportunities for effective collaboration between opioid treatment and other drug treatment providers, people with lived experience, public health, and overdose prevention programs to support hepatitis elimination. Presenters will share models for integrating hepatitis prevention, testing, and treatment into opioid treatment programs and syringe services programs (SSPs), highlighting how cross-sector collaboration and community engagement can drive more equitable and effective outcomes.

Learning Objectives:

At the completion of this activity, participants will:
  • Recall key local, state and national viral hepatitis elimination efforts, the importance of collaboration with opioid treatment providers to support these efforts.
  • Describe how opioid treatment providers can integrate hepatitis services, such as vaccination, testing, linkage to care and treatment within their clinics and in collaboration with local partners.
  • Identify key resources to support integration of hepatitis services into opioid treatment programs.
  • Assess how to meaningfully engage and support people with lived experience in the design and implementation of hepatitis services within opioid treatment and overdose prevention programs.